Nasal Drugs Show Promise for Slowing Parkinson’s Disease Progression in Lab Study

'A remarkable advance' if results can be replicated, Rush researcher says

Translate to Spanish or other 102 languages!

Potential new treatments for Parkinson’s disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.

Mega Doctor News

- Advertisement -

By Rush University Medical Center 

Newswise — Potential new treatments for Parkinson’s disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.

In a study published in Nature Communications, Rush researchers found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy bodies are hallmarks of Parkinson’s disease, the most common movement disorder affecting about 1.2 million people in the United States and Canada.

- Advertisement -

“Currently, there are no treatments that slow the progression of Parkinson’s disease — they only treat the symptoms,” says Kalipada Pahan, PhD, the Floyd A. Davis Professor of Neurology at Rush University Medical Center, and a research career scientist at the Jesse Brown VA Medical Center, who led the study.

Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disorder called multiple system atrophy (MSA). “At present, there is also no effective treatment for dementia with Lewy bodies and multiple system atrophy,” Pahan says. “Understanding how these diseases work is important to developing effective drugs that inhibit alpha-synuclein pathology, protect the brain, and stop the progression of Lewy body diseases.”

The lab-developed peptides tested in the study are known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD). The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson’s disease. The treatments also improved the mice’s gait, balance, and other motor functions. “If these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders,” Pahan says.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Keep Thanksgiving Stress-Free with STHS Food Safety Tips

The holiday season is a time for gathering with loved ones, celebrating family traditions and enjoying home-cooked meals. 

Cybersecurity Alert as Hackers Exploit Computer and Smartphone Vulnerabilities

Federal cybersecurity authorities are urging computer and smartphone users to keep their devices updated following reports of actively exploited security vulnerabilities affecting Apple products and Google’s Chrome browse

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.
- Advertisement -